METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTAGONISTS
    1.
    发明申请
    METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTAGONISTS 审中-公开
    通过管理抗CD2拮抗剂预防或治疗T细胞恶性肿瘤的方法

    公开(公告)号:US20110280868A1

    公开(公告)日:2011-11-17

    申请号:US12466852

    申请日:2009-05-15

    摘要: The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof.

    摘要翻译: 本发明包括CD2拮抗剂,优选MEDI-507,其类似物,衍生物或抗原结合片段作为单一药物治疗用于预防,治疗,治疗或改善癌症,特别是T细胞的用途 恶性肿瘤,或其一种或多种症状。 本发明还包括CD2拮抗剂,优选MEDI-507,其类似物,衍生物或其抗原结合片段与其它癌症疗法的组合的用途。 本发明提供药物组合物,其包含有效预防,治疗,治疗或改善癌症,特别是T细胞恶性肿瘤的CD2拮抗剂,优选MEDI-507,其类似物,衍生物或抗原结合片段,或一种 或更多的症状。